论文部分内容阅读
CA_(125)是卵巢上皮性癌的一种新的肿瘤标志物,采用高灵敏度的免疫放射分析(IRMA)方法来测定,已广泛用以鉴别诊断卵巢良、恶性肿瘤和预后判断。本文采用IRMA方法检测卵巢肿瘤患者血清的CA_(125)值,其结果报道如下。 对象和方法 一、对象:卵巢恶性肿瘤患者75例,其中卵巢上皮性癌61例,卵巢上皮交界癌7例,卵巢性索—间质瘤4例,卵巢生殖细胞瘤4例。子宫颈癌和子宫内膜癌36例,卵巢良性肿瘤38例,年龄23～70岁,均经病理证实。另选正常妇女40例为对照组,年龄25～60岁,全部经妇科体检未发现盆腔肿物及肝功能正常者。 二、方法:肿瘤组血清标本均为手术和治疗前一周内清晨禁食采集,采集后2小时内以2000r/min离心15分钟,取血清放置-20℃低温冰箱内保存备用。CA_(125) IRMA kit由美国CENTOCOR公司供给,操作方法按说明书。仪器使用中国科学技术大学科技实业总公司生产的GC-911 γ放射免疫计数器。
CA_(125) is a novel tumor marker of epithelial ovarian cancer. It is determined by high-sensitivity immunoradiometric assay (IRMA) and has been widely used to differentiate ovarian benign and malignant tumors and prognosis. In this study, IRMA method was used to detect serum CA125 levels in patients with ovarian cancer. The results are reported below. Subjects and Methods 1. Object: 75 cases of ovarian cancer patients, including 61 cases of epithelial ovarian cancer, 7 cases of ovarian epithelial junction cancer, 4 cases of ovarian cord-stromal tumors, 4 cases of ovarian germinoma. There were 36 cases of cervical cancer and endometrial cancer, and 38 cases of benign ovarian tumors, aged 23 to 70 years, all confirmed by pathology. Another 40 normal women were selected as the control group, aged 25 to 60 years old. All pelvic masses and normal liver function were not found in the gynecological examination. 2. Methods: Serum specimens of tumor group were collected by fasting within one week before surgery and treatment, centrifuged at 2000r/min within 2 hours after collection, and serum was placed in a low-temperature refrigerator at -20°C for later use. The CA_(125) IRMA kit is supplied by CENTOCOR, USA. The method of operation is in accordance with the instructions. The instrument uses the GC-911 gamma radioimmunoassay counter produced by the Science and Technology Industry Corporation of the University of Science and Technology of China.